Artax Biopharma
  • Resources
  • Partners
  • Media
  • Contact us
  • Our Approach
  • Our Patients
  • About Artax
  • Our Pipeline and Progress

Resources

  • Feature Jan 22, 2025

    Artax Biopharma achieves clinical validation of first-in-class, oral,  Nck modulator AX-158 for autoimmune disease in phase 2a study

    Cambridge, MA, January 22, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the…
    • Scientific Publication
    • Press Releases
    • Media
    • Press Releases
    Oct 1, 2024

    Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting

    Cambridge, MA, October 1, 2024 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on…
    • Press Releases
    Aug 13, 2024

    Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

    AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression. Psoriasis biomarker panel and PASI scores…
    • Press Releases
    Aug 6, 2024

    Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024

    Strong support from existing shareholders which includes Lilly, Advent Life Sciences, Columbus Ventures, Sound Bioventures and Belinda Termeer Cambridge,…
    • Blog
    May 20, 2024

    Oral Nck modulators: a new, unprecedented approach to autoimmune diseases

    We all are searching for a universal way to treat autoimmune disease: an oral to…
    • Press Releases
    Feb 13, 2024

    Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158

    Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158
    • Press Releases
    Jan 4, 2024

    Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal2024 Year

    Former Board Chair Dr. Rob Armstrong Now Artax CEO as Joseph Lobacki Moves to Advisory…
    • Press Releases
    Nov 9, 2023

    Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

    Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study Patient Enrollment Expected to…
    • Press Releases
    Jun 1, 2023

    Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases 

    Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with…
    • Press Releases
    Mar 7, 2023

    Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company’s Board of Directors

    Company Welcomes Dr. Hoekema, a Biotech Veteran with a Track Record of Successful Industry Collaborations
Previous
1 2 3 4
Next

1 in 10 individuals is affected by autoimmune disease –
join our mission to treat them

Interested in learning more?

Ask us a question – the Artax team can help you

Get in touch
Clinical trials participation

Help us evaluate Nck modulation in clinical trials

About clinical trials
Partner with Artax

Explore Nck modulators for autoimmune conditions

About partnering with Artax

© Artax Biopharma. All Rights Reserved.

Terms of Use | Privacy Policy

Artax Biopharma
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}